These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8381638)

  • 1. Virucidal effects of glucose oxidase and peroxidase or their protein conjugates on human immunodeficiency virus type 1.
    Yamaguchi Y; Semmel M; Stanislawski L; Strosberg AD; Stanislawski M
    Antimicrob Agents Chemother; 1993 Jan; 37(1):26-31. PubMed ID: 8381638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virucidal effect of myeloperoxidase on human immunodeficiency virus type 1-infected T cells.
    Chochola J; Yamaguchi Y; Moguilevsky N; Bollen A; Strosberg AD; Stanislawski M
    Antimicrob Agents Chemother; 1994 May; 38(5):969-72. PubMed ID: 8067778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lethal oxidative damage to human immunodeficiency virus by human recombinant myeloperoxidase.
    Moguilevsky N; Steens M; Thiriart C; Prieels JP; Thiry L; Bollen A
    FEBS Lett; 1992 May; 302(3):209-12. PubMed ID: 1318224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of human immunodeficiency virus type 1 by the amine oxidase-peroxidase system.
    Klebanoff SJ; Kazazi F
    J Clin Microbiol; 1995 Aug; 33(8):2054-7. PubMed ID: 7559947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxidase-mediated virucidal systems.
    Belding ME; Klebanoff SJ; Ray CG
    Science; 1970 Jan; 167(3915):195-6. PubMed ID: 4311694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro.
    Montefiori DC; Zhou JY
    Antiviral Res; 1991 Jan; 15(1):11-25. PubMed ID: 1709802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme immunoconjugates utilizing glucose oxidase and myeloperoxidase are cytotoxic to Candida tropicalis.
    Casentini-Borocz D; Bringman T
    Antimicrob Agents Chemother; 1990 May; 34(5):875-80. PubMed ID: 2163245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro cytolysis of myeloma tumor cells with glucose oxidase and lactoperoxidase antibody conjugates.
    Pene J; Rousseau V; Stanislawski M
    Biochem Int; 1986 Aug; 13(2):233-43. PubMed ID: 3768010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.
    Callahan LN; Phelan M; Mallinson M; Norcross MA
    J Virol; 1991 Mar; 65(3):1543-50. PubMed ID: 1995952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immunotoxin system intended for bone marrow purging composed of glucose oxidase and lactoperoxidase coupled to monoclonal antibody 097.
    Ito HO; Morizet J; Coulombel L; Goavec M; Rousseau V; Bernard A; Stanislawski M
    Bone Marrow Transplant; 1989 Sep; 4(5):519-27. PubMed ID: 2790330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RD6-2198, a novel betain-type fluoroalkylated oligomer, inhibits the replications of human immunodeficiency virus type 1 and other enveloped viruses.
    Fujiwara M; Ashida N; Okamoto M; Mizuta T; Ide T; Hanasaki Y; Katsuura K; Sawada H; Shigeta S; Konno K; Yokota T; Baba M
    Antiviral Res; 1998 May; 38(2):141-9. PubMed ID: 9707376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibitory activity of polyhydroxycarboxylates derived from phenolic compounds against human immunodeficiency virus replication.
    Schols D; Wutzler P; Klöcking R; Helbig B; De Clercq E
    J Acquir Immune Defic Syndr (1988); 1991; 4(7):677-85. PubMed ID: 1675677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein.
    Erice A; Balfour HH; Myers DE; Leske VL; Sannerud KJ; Kuebelbeck V; Irvin JD; Uckun FM
    Antimicrob Agents Chemother; 1993 Apr; 37(4):835-8. PubMed ID: 8494381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
    Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
    J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.
    Gorny MK; Conley AJ; Karwowska S; Buchbinder A; Xu JY; Emini EA; Koenig S; Zolla-Pazner S
    J Virol; 1992 Dec; 66(12):7538-42. PubMed ID: 1433529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assays to detect and characterize human immunodeficiency virus type 1 (HIV-1) receptor antagonists, compounds that inhibit binding of the HIV-1 surface glycoprotein, gp120, to the CD4 receptor on human T lymphocytes.
    Clancy J; Tait-Kamradt A; Petitpas J; Manousos M; McGuirk PR; Subashi T; Watts P; Wondrack L
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2008-13. PubMed ID: 7811011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virucidal effect of stimulated eosinophils on human immunodeficiency virus type 1.
    Klebanoff SJ; Coombs RW
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):25-9. PubMed ID: 8825615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of peroxidase and glucose oxidase by H2O2 and iodide during in vitro thyroglobulin iodination.
    Wildberger E; Kohler H; Jenzer H; Kämpf J; Studer H
    Mol Cell Endocrinol; 1986 Jul; 46(2):149-54. PubMed ID: 3013706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.
    Yahi N; Sabatier JM; Baghdiguian S; Gonzalez-Scarano F; Fantini J
    J Virol; 1995 Jan; 69(1):320-5. PubMed ID: 7983725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication.
    Steinkasserer A; Harrison R; Billich A; Hammerschmid F; Werner G; Wolff B; Peichl P; Palfi G; Schnitzel W; Mlynar E
    J Virol; 1995 Feb; 69(2):814-24. PubMed ID: 7815548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.